First-line Atezolizumab With Bevacizumab for HCC

Amit Mahipal, MD, of University Hospitals Seidman Cancer Center, discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for hepatocellular carcinoma.

Dr. Mahipal describes the benefits of the combination and reviews the differences between Child-Pugh and ALBI scores for patients, as well as the disparities that affect certain patient populations with HCC.

00:00 Benefits of Atezo/Bev

01:39 Comparing CP and ALBI Scores

03:48 Atezo/Bev for CP A-B7

05:37 CP Liver Function Groups

06:31 Therapy for CP 8+

07:34 Disparities in HCC Care

09:10 Future Research on Atezo/Bev